Similarly, tofacitinib, a newly developed JAK inhibitor for RA treatment, significantly reduces the expression of key glycolytic enzyme-related genes and enzymes in synovial cells of patients with RA, decreases mitochondrial membrane potential, and increases oxidative phosphorylation energy metabolism to treat RA (149) (Table 1). Here, HK1 is linked to rheumatoid arthritis.